2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.28 Cuesta

PP01.28 Cuesta - Poster

Pdf Summary

A systematic review and meta-analysis compared pathologic response rates in resectable NSCLC patients undergoing neoadjuvant PD-1 monotherapy or chemoimmunotherapy (chemoIO) based on PD-L1 expression levels. Studies published before 10/2023 were analyzed, with outcomes focused on pathological complete response (pCR) and major pathological response (MPR) rates in different PD-L1 subgroups. The meta-analysis found that PD-L1 expression influenced both pCR and MPR rates in neoadjuvant treatments. ChemoIO showed higher pCR/MPR rates overall, but 35% of patients with PD-L1 50% achieved MPR after PD-1 monotherapy, indicating promising activity in specific biomarker cohorts. Future research will explore the correlation between PD-L1 expression and recurrence outcomes for these treatment approaches. The study highlights the potential of using PD-L1 as a biomarker for response prediction in early-stage NSCLC treatment regimens. Key references include notable studies on PD-L1 expression as a predictive tool in NSCLC therapy. The analysis excluded studies with dual-immune checkpoint blockade and radiation interventions, focusing solely on neoadjuvant IO and chemoIO without XRT or dual-IO. This study enhances understanding of the impact of PD-L1 expression on treatment response in resectable NSCLC, paving the way for more tailored and effective therapies in the future.

Keywords

systematic review

meta-analysis

resectable NSCLC

neoadjuvant therapy

PD-1 monotherapy

chemoimmunotherapy

PD-L1 expression

pathological response

pCR rates

MPR rates